December 11, 2017
Shionogi Signs Strategic Digital Transformation Agreement with Accenture
 
Agreement includes talent-development program to drive pharmaceutical company’s digital transformation and leverage IT cost savings
 
TOKYO; Dec. 11, 2017 – Accenture (NYSE: ACN) has signed consulting and strategic outsourcing agreements with Shionogi & Co., Ltd. ("Shionogi") and its subsidiary company, Shionogi Digital Science Co., Ltd. ("Shionogi Digital Science”) to help Shionogi with its digital transformation initiative.

As part of the consulting agreement, Accenture will help Shionogi envision and develop the IT strategy and roadmap for its digital transformation initiative as the company accelerates its investments in cloud, cybersecurity and other digital technologies – which Accenture refers to as “New IT.” In addition, Accenture will help Shionogi enhance the digital talent and capabilities of its IT division through a knowledge-transfer program and also help Shionogi accelerate the digitalization of its business and enhance its data-utilization capabilities.
 
Under the outsourcing agreement, Accenture will provide Shionogi with application development, application maintenance, infrastructure operation and infrastructure maintenance services for its enterprise resource planning (ERP) system. The agreement, which has a term of seven years, is intended to help Shionogi reduce the operating and maintenance costs of its IT system, with the savings used to help Shionogi enhance its digital resources and capabilities and enable its IT division to deliver tangible business value. The services will be delivered primarily from Accenture delivery centers in Manila and Cebu in the Philippines, which are part of the Accenture Global Delivery Network of more than 50 locations around the world.
 
These two contracted projects will be a key element of Shionogi’s digital transformation initiative and will enable Accenture to further expand its business in the Kansai region.
 
“As a drug discovery-based pharmaceutical company, our goal is to contribute to a more vigorous society through improved healthcare,” said Takuko Sawada, director and senior executive officer of Shionogi & Co., Ltd. “To ensure sustainable growth and enhance our specialized business operations, we established six subsidiaries, including Shionogi Digital Science in April 2017. Through our initiatives with Accenture, we will streamline business operations by leveraging New IT, which will enhance our ability to leverage data analytics, enabling us to respond quickly to the rapidly evolving business landscape and promote innovative new drugs.”
 
Hideki Maruyama, president of Shionogi Digital Science Co., Ltd., said, “Leveraging New IT as well as traditional IT, we aim to support Shionogi Group’s policy of supplying the best possible medicine to protect the health and well-being of the patients we serve. With Accenture’ support, we will standardize and streamline our ERP systems and further drive innovation by creating an IT organization that can rapidly respond to a changing business landscape.”
 
Mitsuru Nagata, managing director of Accenture’s Life Sciences practice in Japan, said, “We are excited to help Shionogi implement its digital growth strategy. Leveraging our expertise in digital transformation, our knowledge of and experience in the pharmaceutical industry, and our globally industrialized IT processes, we will help support Shionogi’s sustained growth while expanding our business in the Kansai region, where there is a growing need for innovation.”
 
About Shionogi & Co., Ltd.
Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic diseases and oncology/immunology. Contributing to the health and QOL of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit www.shionogi.co.jp/en/.
 
About Accenture
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions – underpinned by the world’s largest delivery network – Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With approximately 425,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com
 
# # #
 
 
Contact:
 
Yoshimasa Kyokawa
Shionogi & Co., Ltd.
+81 6 6209 7885
+81 6 6229 9596 (Fax)
 
Shigeo Masuda
Accenture
+81 45 330 7157
shigeo.masuda@accenture.com